Physician profile
May L Ko
NPI 1528447653
$18,174.43
in general payments reported to CMS, 2019-2025
31 companies · $3,751 in 2025
The $3,751 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,628 · 2022: $4,169 · 2023: $3,900 · 2024: $4,726 · 2025: $3,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,890.26 |
| Education | $486.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,132.78 | 2021-2025 | |
| Janssen Biotech, INC. | $2,742.77 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,442.27 | 2021-2025 | |
| Lilly USA, LLC | $1,173.68 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $1,007.71 | 2021-2025 | |
| Genzyme Corporation | $905.90 | 2021-2025 | |
| Amgen INC. | $886.08 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $774.79 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $728.35 | 2022-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $691.74 | 2021-2024 | Tremfya |
| Incyte Corporation | $637.26 | 2021-2025 | Opzelura |
| Ucb, INC. | $522.32 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $440.46 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $439.81 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $388.74 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $374.55 | 2021-2024 | Ilumya, Absorica Ld, Winlevi |
| Kerecis Limited | $364.83 | 2023-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Leo Pharma INC. | $331.76 | 2021-2025 | Adbry, Anzupgo |
| Sanofi-Aventis U.S. LLC | $280.97 | 2021-2024 | |
| Galderma Laboratories, L.P. | $230.10 | 2022-2025 | Aklief, Oracea, Epsolay |
| Botanix Sb INC | $143.35 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $98.14 | 2022-2025 | |
| Organon LLC | $82.30 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.26 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.74 | 2021-2024 | Duobrii, Siliq |
| Sebela Pharmaceuticals INC. | $60.39 | 2022-2023 | Naftin, Pramosone |
| Ani Pharmaceuticals, INC. | $48.83 | 2025 | Oxistat |
| Almirall LLC | $39.02 | 2021 | |
| Strata Skin Sciences, INC. | $16.27 | 2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $15.65 | 2025 | Valchlor |
| Smith+Nephew, INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.